Warning! GuruFocus detected
2 Severe warning signs
with MOB.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Moberg Pharma AB
NAICS : 325412
ISIN : SE0020353928
Compare
Compare
Traded in other countries / regions
MOB.SwedenMBGPF.USAMB8.GermanyMOBs.UK IPO Date
2011-05-26Description
Moberg Pharma AB is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of compounds. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 70.79 | |||||
| Equity-to-Asset | 0.97 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.22 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 8.11 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 42.9 | |||||
| 3-Year EPS without NRI Growth Rate | -38.6 | |||||
| 3-Year FCF Growth Rate | 31 | |||||
| 3-Year Book Growth Rate | -38.6 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 154.39 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 65.6 | |||||
| 9-Day RSI | 54.13 | |||||
| 14-Day RSI | 48.4 | |||||
| 3-1 Month Momentum % | -14.36 | |||||
| 6-1 Month Momentum % | -34.65 | |||||
| 12-1 Month Momentum % | -78.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 17.95 | |||||
| Quick Ratio | 17.69 | |||||
| Cash Ratio | 17.54 | |||||
| Days Inventory | 622.59 | |||||
| Days Sales Outstanding | 257.54 | |||||
| Days Payable | 706.61 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -89.7 | |||||
| Shareholder Yield % | -98 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 64.37 | |||||
| Operating Margin % | -3310.88 | |||||
| Net Margin % | -2600.26 | |||||
| FCF Margin % | -917.57 | |||||
| ROE % | -33.92 | |||||
| ROA % | -32.89 | |||||
| ROIC % | -44.78 | |||||
| 3-Year ROIIC % | -364.84 | |||||
| ROC (Joel Greenblatt) % | -7208.85 | |||||
| ROCE % | -42.42 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shiller PE Ratio | 0.24 | |||||
| PS Ratio | 30.72 | |||||
| PB Ratio | 0.53 | |||||
| Price-to-Tangible-Book | 0.95 | |||||
| EV-to-EBIT | -0.23 | |||||
| EV-to-EBITDA | -3.86 | |||||
| EV-to-Revenue | 7.44 | |||||
| EV-to-FCF | -0.46 | |||||
| Price-to-Net-Current-Asset-Value | 1.29 | |||||
| Price-to-Net-Cash | 1.32 | |||||
| Earnings Yield (Greenblatt) % | -434.47 | |||||
| FCF Yield % | -24.91 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Moberg Pharma AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 9.811 | ||
| EPS (TTM) (kr) | -5.6 | ||
| Beta | 1.34 | ||
| 3-Year Sharpe Ratio | 0.14 | ||
| 3-Year Sortino Ratio | 0.2 | ||
| Volatility % | 120.96 | ||
| 14-Day RSI | 48.4 | ||
| 14-Day ATR (kr) | 0.469214 | ||
| 20-Day SMA (kr) | 7.649 | ||
| 12-1 Month Momentum % | -78.18 | ||
| 52-Week Range (kr) | 6.335 - 39.78 | ||
| Shares Outstanding (Mil) | 46.69 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Moberg Pharma AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Moberg Pharma AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Moberg Pharma AB Frequently Asked Questions
What is Moberg Pharma AB(OSTO:MOB)'s stock price today?
The current price of OSTO:MOB is kr7.74. The 52 week high of OSTO:MOB is kr39.78 and 52 week low is kr6.34.
When is next earnings date of Moberg Pharma AB(OSTO:MOB)?
The next earnings date of Moberg Pharma AB(OSTO:MOB) is 2025-05-13.
Does Moberg Pharma AB(OSTO:MOB) pay dividends? If so, how much?
Moberg Pharma AB(OSTO:MOB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers